
Alumis Inc (ALMS) Stock Forecast & Price Target
Alumis Inc (ALMS) Analyst Ratings
Bulls say
Alumis Inc. showcases a promising outlook due to its innovative pipeline, particularly the potential of envudeucitinib (envu), which is positioned favorably compared to current market leaders like Takeda's treatments. The company's focus on precision medicine and targeted therapies aims to revolutionize treatment modalities for autoimmune disorders, which could translate into significant market opportunities. With favorable cost of goods sold (COGS) metrics and improvements anticipated in key efficacy criteria, Alumis is strategically positioned to become a leader in the TYK2 inhibitor segment, enhancing its growth potential and value proposition in the biopharmaceutical landscape.
Bears say
Alumis Inc faces significant uncertainties regarding the efficacy and timely advancement of its clinical programs, particularly concerning ESK-001 and envu, which could adversely affect commercialization and regulatory approval timelines. The reported efficacy plateau of rival products, as demonstrated by Takeda’s zasuticinib, raises questions regarding the competitive positioning of Alumis's pipeline, suggesting potential challenges in achieving market uptake. Additionally, the company’s current estimated enterprise value of approximately $730 million may not adequately reflect the increased risks of regulatory delays, competitive threats, and possible dilution, contributing to a negative outlook on its stock.
This aggregate rating is based on analysts' research of Alumis Inc and is not a guaranteed prediction by Public.com or investment advice.
Alumis Inc (ALMS) Analyst Forecast & Price Prediction
Start investing in Alumis Inc (ALMS)
Order type
Buy in
Order amount
Est. shares
0 shares